key: cord-0908141-wqu3700r
authors: Muir, Keith W.; Perry, Richard J.
title: The International Cerebral Venous Thrombosis Consortium report on cerebral venous thrombosis following vaccination against SARS‐CoV‐2
date: 2021-09-14
journal: Eur J Neurol
DOI: 10.1111/ene.15085
sha: 18ad7b38f18346bbb6dcabb89825cb5648c27f03
doc_id: 908141
cord_uid: wqu3700r

In this issue, Krzywicka and colleagues describe the cases of cerebral venous sinus thrombosis (CVST) following vaccination against SARS-Cov-2 reported to the European Medicines Agency (EMA) via their post-marketing pharmacovigilance system. They compare features and outcomes both between different vaccines, and with a historical dataset from three European hospitals on sporadic CVST pre-COVID-19 (Krzywicka et al., 2021).

In this issue, Krzywicka The authors note that critical information is missing from their study. They were unable to confirm the accuracy of CVST diagnosis. Furthermore, the denominator for the population administered each of the vaccines investigated is absent. Detail of clinical cases is very limited and may be selectively reported. While there were no reported instances of COVID-19 infection among reported post-

Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: evaluation, management, and scientific questions

Cerebral venous sinus thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)

Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases

COVID-19 vaccine-Associated cerebral venous thrombosis in germany

Medicines & Healthcare Products Regulatory Agency Coronavirus vaccine -weekly summary of Yellow Card reporting

6-Month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records